|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.930 USD | +1.02% |
|
+0.73% | -27.96% |
| Nov. 13 | Mimedx Provides Update on Epieffect®? Randomized Controlled Trial | CI |
| Oct. 29 | MiMedx Group, Inc., Q3 2025 Earnings Call, Oct 29, 2025 |
| Capitalization | 1.03B 882M 826M 770M 1.42B 92.37B 1.55B 9.67B 3.73B 43.63B 3.85B 3.77B 160B | P/E ratio 2025 * |
20.4x | P/E ratio 2026 * | 22.8x |
|---|---|---|---|---|---|
| Enterprise value | 1.03B 882M 826M 770M 1.42B 92.37B 1.55B 9.67B 3.73B 43.63B 3.85B 3.77B 160B | EV / Sales 2025 * |
2.52x | EV / Sales 2026 * | 2.47x |
| Free-Float |
97.55% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: MiMedx Group, Inc.
More recommendations
More press releases
More news
| 1 day | +1.02% | ||
| 1 week | +0.73% | ||
| Current month | +0.73% | ||
| 1 month | -12.94% | ||
| 3 months | -2.94% | ||
| 6 months | +9.31% | ||
| Current year | -27.96% |
| 1 week | 6.62 | 7.06 | |
| 1 month | 6.32 | 7.77 | |
| Current year | 5.79 | 9.71 | |
| 1 year | 5.79 | 10.14 | |
| 3 years | 2.43 | 10.14 | |
| 5 years | 2.43 | 15.99 | |
| 10 years | 0.95 | 18.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 61 | 2023-01-26 |
Douglas Rice
DFI | Director of Finance/CFO | 59 | 2023-07-04 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
James Bierman
BRD | Director/Board Member | 72 | 2019-06-18 |
M. Wilsey
CHM | Chairman | 72 | 2019-06-18 |
K. Newton
BRD | Director/Board Member | 62 | 2019-06-18 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.02% | +0.73% | -26.82% | +121.41% | 1.02B | ||
| -8.78% | -6.82% | - | - | 847M | ||
| -4.40% | +2.82% | +146.92% | +108.03% | 324M | ||
| +0.81% | +1.63% | +126.36% | +16.36% | 89.71M | ||
| Average | -2.84% | -0.62% | +82.16% | +81.93% | 569.11M | |
| Weighted average by Cap. | -3.40% | -0.87% | +22.17% | +111.78% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 407M 350M 328M 306M 565M 36.67B 614M 3.84B 1.48B 17.32B 1.53B 1.5B 63.33B | 416M 358M 335M 312M 577M 37.45B 627M 3.92B 1.51B 17.69B 1.56B 1.53B 64.67B |
| Net income | 48.22M 41.45M 38.83M 36.2M 66.85M 4.34B 72.72M 454M 175M 2.05B 181M 177M 7.49B | 49.82M 42.83M 40.12M 37.4M 69.07M 4.48B 75.13M 469M 181M 2.12B 187M 183M 7.74B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
837
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 6.930 $ | +1.02% | 527,667 |
| 25-12-04 | 6.860 $ | -1.44% | 669,315 |
| 25-12-03 | 6.960 $ | +3.57% | 633,937 |
| 25-12-02 | 6.720 $ | +0.75% | 545,806 |
| 25-12-01 | 6.670 $ | -3.05% | 723,754 |
Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm EST
More quotesSell
Buy

Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.930USD
Average target price
12.20USD
Spread / Average Target
+76.05%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MDXG Stock
Select your edition
All financial news and data tailored to specific country editions
















